A Real-World Observational Study of Second-Line Anti-TNFα Treatment in Patients with Ulcerative Colitis who Received Vedolizumab as a First-Line Biologic

Clicks: 3
ID: 313655
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #15 of 38 articles by views in Crohn s & Colitis 360

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Many patients with ulcerative colitis (UC) require treatment with more than one biologic during their lifetime. This real-world observational study assessed the effectiveness of second-line anti-tumor necrosis factor α (anti-TNFα) treatment in patients with UC who had previously received vedolizumab as a first-line biologic. Methods This retrospective study included biologic-naive adult patients with UC who were treated with vedolizumab as a first-line biologic at a large, multicenter, private gastroenterology practice in Texas, United States, between January 1, 2018, and December 31, 2020. Outcomes were assessed by partial Mayo score, not including endoscopic data. Results In total, 260 patients received vedolizumab. Treatment was discontinued in 53 patients who then received a second-line anti-TNFα treatment. Of all patients treated with a second-line anti-TNFα treatment, 14/53 (26.4%) had a clinical response and 11/53 (20.8%) had clinical remission at 12 months. Accounting for anti-TNFα treatment discontinuations, 14/26 patients (53.8%) had a clinical response and 11/26 patients (42.3%) had clinical remission at 12 months, respectively. In an exploratory analysis of the patients who received vedolizumab as a first-line biologic, 188/260 (72.3%) remained on treatment at 12 months and 149/188 (79.3%) of them had clinical remission. For those with a partial Mayo score ≥ 5 at baseline, onset of vedolizumab action was observed in 49.6% by week 2 and in 87.2% by week 6. Conclusion Second-line anti-TNFα treatments were effective following vedolizumab as a first-line biologic. Most patients had onset of action of vedolizumab within 6 weeks and had clinical remission at 12 months.
Reference Key
openalex_W7161476801 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Chiahung Chou, Marie Sanchirico, Precious Anyanwu, Lucinda J. Van Anglen, Timothy E. Ritter
Journal Crohn s & Colitis 360
Year 2026
DOI
10.1093/crocol/otag042
URL
https://doi.org/10.1093/crocol/otag042
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.